药物性胆汁淤积性肝病
本文综述药物性胆汁淤积性肝病的诊断思路与新临床表型,包括继发性硬化性胆管炎和胆管消失综合征,并概述风险因素、遗传决定因素及肝胆转运蛋白病理生理学,同时讨论管理、不确定领域和未来方向。
要点
- 药物性胆汁淤积性肝病需排除肝胆恶性肿瘤、胆总管结石、病毒性肝炎胆汁淤积型、脓毒症胆汁淤积、原发性和继发性胆管炎及右心衰竭等竞争性病因。
- 检查点抑制剂等药物可导致继发性硬化性胆管炎,多种新草药和膳食补充剂可导致胆汁淤积性肝损伤。
- 近十年已识别多种药物性胆汁淤积的遗传风险因素,肝胆转运蛋白相关的病理生理学得到更好定义。
核心结论
- 药物性胆汁淤积性肝病是肝酶升高且以碱性磷酸酶升高为主时的重要且常具挑战性的鉴别诊断。
- 自2011年Hepatology上次发表药物性胆汁淤积综述以来,在临床表型、新致病药物、风险因素、病理生理学和遗传决定因素方面已取得重要进展。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 药物导致的继发性硬化性胆管炎已在几种不同药物中得到充分记录。
- 检查点抑制剂是已显示可导致继发性硬化性胆管炎的药物类型之一。
- 多种新草药和膳食补充剂最近已显示可导致胆汁淤积性肝损伤。
- 过去十年已识别多种药物性胆汁淤积的遗传风险因素,胆汁淤积性损伤背后的发病机制得到更好定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cholestatic DILI is an important and frequently challenging differential diagnosis in patients presenting with elevated liver tests with predominant elevation in alkaline phosphatase. A number of competing etiologies need to be ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms of viral hepatitis, cholestasis of sepsis, primary and secondary cholangitis, and right-sided cardiac failure to name a few. Important advances have occurred in the understanding and knowledge of the clinical phenotypes, new etiological agents, risk factors, pathophysiology, and genetic determinants of drug-induced cholestasis since the last review on drug-induced cholestasis was published in Hepatology in 2011. Secondary sclerosing cholangitis (SSC) due to drugs has been well documented for several different drugs. Checkpoint inhibitors are one of the types of drugs shown to lead to secondary sclerosing cholangitis. Several new herbal and dietary supplements have recently been shown to lead to cholestatic liver injury. A number of genetic risk factors for cholestasis due to drugs have been identified in the last decade, and the pathogenesis behind cholestatic injury is better defined. In this review, the focus is on diagnostic approach and description of new clinical phenotypes such as secondary sclerosing cholangitis and vanishing bile duct syndrome. Furthermore, the review provides an overview of the risk factors, genetic determinants, and the pathophysiology of hepatobiliary transporters leading to cholestasis. Management, areas of uncertainty, and future direction are also presented.
引用
- Bjornsson ES, Devarbhavi HC. Drug-induced cholestatic liver diseases. Hepatology. 2024. PMID: 39121063. doi:10.1097/HEP.0000000000001052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。